Thomas H. Kean
Trade Performance Intelligence
Score: 8/10Performance calculated from trade date to most recent market close. Real-time stock data from Financial Modeling Prep. This is not financial advice.
Stock Price at Trade vs. Today
Real market data showing how each stock moved since the congress member traded it.
Suspicious Timing Detected
5 flagsRep. Kean sold $15,001-$50,000 in $JNJ on 2025-11-20 — 15 days before the 'Skinny Labels, Big Savings Act' (HR6485) was introduced, a bill aiming to reduce patent infringement risk for generic drug manufacturers.
Rep. Kean sold $15,001-$50,000 in $JNJ on 2025-11-20 — 61 days before HR7165 was introduced, which would increase operational costs for pharmaceutical companies using foreign laboratories.
Rep. Kean bought $1,001-$15,000 in $TXN on 2025-11-26 — 70 days before the 'Federal Acquisition Security Council Improvement Act of 2026' (HR7274) was introduced, a bill strengthening authority to restrict certain technologies.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
GAP Supply Act
The GAP Supply Act (HR7528) was introduced on February 12, 2026, and referred to the House Committee on Energy and Commerce. This bill aims to allow outsourcing facilities to continue supplying drugs during shortages for an additional 180 days, providing regulatory stability for pharmaceutical supply chains. The bill is in an early legislative stage.
Break Up Big Medicine Act
The 'Break Up Big Medicine Act' (S.3822), introduced by Senator Warren and cosponsored by Senator Hawley, aims to prohibit common ownership between pharmacy benefit managers, insurers, drug/medical device wholesalers, and certain medical service providers. This bill, currently in the early stages of being referred to the Committee on the Judiciary, targets the vertical integration prevalent in the healthcare sector, potentially forcing divestitures for large pharmaceutical and healthcare conglomerates. While the bill does not specify direct funding, its provisions could significantly restructure the healthcare market.
Skinny Labels, Big Savings Act
The 'Skinny Labels, Big Savings Act' (HR6485) aims to reduce patent infringement risk for generic drug manufacturers by providing a statutory safe harbor, directly reversing the GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc. precedent. This bill, currently in the early stages of the legislative process, would increase market access for generics and biosimilars, benefiting companies like Teva Pharmaceutical Industries Limited ($TEVA) and Viatris Inc. ($VTRS), while potentially increasing competition for innovator drug companies such as Amgen Inc. ($AMGN), Pfizer Inc. ($PFE), Johnson & Johnson ($JNJ), and Merck & Co., Inc. ($MRK).
AI Grand Challenges Act of 2026
The AI Grand Challenges Act of 2026 (S.3809) has been introduced in the Senate and referred to committee. This bill authorizes the National Science Foundation to establish a competitive prize program for AI research and development across various sectors, including national security, health, and energy, but does not appropriate funds. While the bill signals potential future government investment in AI, its early legislative stage and lack of direct funding appropriation mean immediate market impact is limited.
Stop Corporate Inversions Act of 2026
The Stop Corporate Inversions Act of 2026, S3847, aims to increase U.S. tax liabilities for companies that have inverted or plan to invert, potentially reducing net income for affected corporations. This bill is in the early stages, having been referred to the Senate Committee on Finance on February 11, 2026. Companies with significant foreign operations that have previously inverted or might consider it face increased tax burdens if this legislation progresses.
Most Favored Patient Act of 2026
The Most Favored Patient Act of 2026 (HR7837) has been introduced in the House, proposing a most-favored-nation drug pricing model for Medicare-covered drugs by January 1, 2029. This bill, if enacted, would directly reduce revenue for major pharmaceutical companies by mandating the lowest global drug prices. The bill is currently in the early stages of the legislative process, having been referred to the Committees on Energy and Commerce and Ways and Means.
Federal Acquisition Security Council Improvement Act of 2026
HR7274, the Federal Acquisition Security Council Improvement Act of 2026, strengthens the Federal Acquisition Security Council's authority to restrict foreign adversary technology in government supply chains. This legislative action is poised to increase demand for secure, domestically sourced components and technology, directly benefiting U.S.-based technology and defense contractors. Companies with established U.S. manufacturing capabilities and robust supply chain security are positioned to gain market share.
To require the Secretary of Health and Human Services to establish a demonstration program to test mandatory coverage of treatment for wound care for epidermolysis bullosa under the Medicaid program.
HR7877, the "Shane DiGiovanna Act," introduced on March 9, 2026, mandates a nationwide Medicaid demonstration program for epidermolysis bullosa wound care, creating a new, guaranteed revenue stream for pharmaceutical and medical supply companies. This bill directly increases demand for specific over-the-counter medications and wound care supplies by expanding covered services under Medicaid.
Stop Corporate Inversions Act of 2026
The Stop Corporate Inversions Act of 2026 (HR7493) aims to increase the tax burden on companies that have inverted or are considering inversion, particularly in the healthcare and technology sectors, by tightening ownership requirements. This legislation, if enacted, would make future inversions financially unviable and reduce profitability for affected companies. The bill is in an early stage, having been referred to the House Committee on Ways and Means on February 11, 2026.
To amend section 495 of the Public Health Service Act to require inspections of foreign laboratories conducting biomedical and behavioral research to ensure compliance with applicable animal welfare requirements, and for other purposes.
HR7165, if enacted, would increase operational costs and delays for Contract Research Organizations (CROs) and pharmaceutical companies utilizing foreign laboratories for biomedical and behavioral research. This new regulatory burden is expected to reduce profit margins and slow drug development timelines. The bill is currently in its early stages, having been referred to committee on January 20, 2026.
Live Charts
Other Filings by Thomas H. Kean
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.